ArticleBMC pediatrics2026
A comparison of dual vs. single diagnostic code approaches for neonatal opioid withdrawal syndrome surveillance in neonates ≥ 35 weeks gestational age.
Article in BMC pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundUsing dual ICD-10-CM codes for exposure/withdrawal (P04.49 or P96.1, respectively) may be more sensitive for identifying Neonatal Opioid Withdrawal Syndrome (NOWS) than P96.1 alone. There are currently no studies that report on national prevalence using this dual code approach.
objectivesWe examined U.S. national NOWS prevalence trends comparing the dual vs. single code approach for surveillance.
methods2016-2022 cycles of cross-sectional data from the U.S. Healthcare Cost and Utilization Project, Kids' Inpatient Database were used to estimate weighted NOWS prevalence in newborns ≥ 35 weeks excluding iatrogenic cases. Generalized linear models with predictive margins were used to estimate prevalence differences for select sociodemographic factors stratified by race/ethnicity. Select measures of morbidity and mortality were evaluated as secondary outcome measures for NOWS.
resultsThe survey weighted population was 1,084,633 pediatric discharges and crude NOWS prevalence decreased across 2016-2022 cycles. Using dual codes, crude NOWS prevalence doubled overall at 19.05/1000 (95% CI: 18.33, 19.8) (vs. single: 9.48; 95% CI: 9.05, 9.93) and across most factors and was highest in White infants (dual: 25.15; 95% CI: 24.09, 26.26, single: 13.98; 95% CI: 13.27, 14.71). Crude prevalence for Black infants almost tripled (dual: 19.67; 95% CI: 18.46, 20.95, single: 6.19; 95% CI: 5.65, 6.78). Medicaid payer-type (dual: 35.93; 95% CI: 34.6, 37.3, single: 18.12; 95% CI: 17.29, 18.98), lowest ecologic income-quartile (dual: 29.43; 95% CI: 28.12, 30.79, single: 13.72; 95% CI: 12.92, 14.58), and rural hospital-location (dual: 33.22; 95% CI: 30.75, 35.88, single: 13.88; 95% CI: 12.31, 15.66) were factors with the highest crude prevalence. Trends for relative measures for within category comparison of crude prevalence were largely similar but showed greater magnitude of change for survey year and income quartile. In fully adjusted models, effect modification was evident by year, payer type, and income level, for all race/ethnicity comparisons with dual codes, and short-term morbidity risk appeared higher with dual codes (15.2% vs. single 6.2%) whereas length of stay was greater with single code (7.0 vs. 11.7 days).
conclusionsThe dual code approach provides an alternative strategy for NOWS surveillance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.